肝源性ApoJ向肾脏转积累通过破坏TFEB介导的脂质稳态加剧糖尿病肾损伤
本研究探讨载脂蛋白J(ApoJ)在糖尿病肾病(DKD)中的作用。在201例2型糖尿病患者中,循环ApoJ浓度与肾功能不全指标正相关。机制上,ApoJ抑制FBW7介导的mTOR泛素化,增强mTOR与TFEB相互作用,导致脂质失衡和肾纤维化;肝细胞特异性敲除ApoJ或使用拮抗剂MK53可改善糖尿病小鼠肾损伤。
要点
- 循环ApoJ浓度与2型糖尿病患者肾功能不全指标正相关。
- 肝源性ApoJ转积累至肾小管,通过mTOR-TFEB通路破坏脂质稳态。
- ApoJ拮抗剂MK53可恢复脂质稳态并减轻糖尿病小鼠肾损伤。
核心结论
- 肝源性ApoJ向肾脏转积累是糖尿病肾损伤的致病因素,MK53是潜在治疗策略。
研究设计与样本
- 研究纳入201例2型糖尿病患者分析循环ApoJ与肾功能关联,并使用HK2细胞、组织特异性ApoJ敲除小鼠及DKD小鼠模型验证机制。
主要发现
- 2型糖尿病患者循环ApoJ浓度与肾功能不全指标呈正相关。
- DKD小鼠模型中肾脏ApoJ升高伴随脂质积累增加和肾脏结构损伤。
- ApoJ抑制FBW7介导的mTOR泛素化,增强mTOR与TFEB相互作用,导致脂质失衡和肾纤维化。
- 肝细胞特异性敲除ApoJ消除循环ApoJ,阻止其在肾小管积累并改善糖尿病肾损伤。
- ApoJ拮抗剂MK53重新激活TFEB-自噬通路,恢复脂质稳态并减少糖尿病小鼠肾损伤。
临床怎么用
- 循环ApoJ可能作为糖尿病肾病肾功能不全的关联指标。
- 靶向ApoJ-TFEB通路(如MK53)可能成为糖尿病肾病治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Ectopic lipid accumulation in renal tubules induces lipotoxicity and contributes to the progression of diabetic kidney disease (DKD). Apolipoprotein J (ApoJ), a glucose-regulated, liver-derived molecular chaperone, is implicated in systemic metabolic homeostasis. This study aimed to investigate the pathophysiological role of ApoJ in the development of DKD. METHODS: Spearman's r analysis was used to evaluate the association between circulating ApoJ concentrations and renal function in a cohort of 201 individuals with type 2 diabetes mellitus. The pathways were identified by proteomic analyses and subsequently validated using gain- and loss-of-function approaches in proximal tubular epithelial HK2 cells, tissue-specific ApoJ-knockout mice and additional mouse models of DKD. RESULTS: In individuals with type 2 diabetes, circulating ApoJ concentrations were positively associated with indices of renal dysfunction. In murine models of DKD, elevated renal ApoJ was accompanied by increased lipid accumulation and structural kidney injury. Mechanistic studies revealed that ApoJ inhibited FBW7-mediated ubiquitination of mammalian target of rapamycin (mTOR), thereby enhancing mTOR interaction with transcription factor EB (TFEB) in HK2 cells under conditions of nutrient excess, leading to lipid imbalance and renal fibrosis. Hepatocyte-specific deletion of ApoJ eliminated circulating ApoJ, prevented its accumulation in renal tubules and ameliorated diabetic kidney injury. Furthermore, pharmacological blockade with the ApoJ antagonist MK53 reactivated the TFEB-autophagy pathway, restored lipid homeostasis and reduced renal damage in diabetic mice. CONCLUSIONS/INTERPRETATION: Our findings highlight a liver-to-kidney interorgan transfer of pathogenetic ApoJ in diabetic kidney injury and suggest that MK53 represents a potential therapeutic strategy for DKD.
引用
- Duan S, Qin N, Pi J, et al. Liver-to-kidney apolipoprotein J trans-accumulation exacerbates diabetic renal injury by disrupting TFEB-mediated lipid homeostasis. Diabetologia. 2026. PMID: 42467084. doi:10.1007/s00125-026-06801-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。